Navigation Links
Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement
Date:7/10/2013

n July 2013, Array began a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

Array Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Array's potential to earn future milestone and royalty payments under the agreement with Loxo, the potential for the results of preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate, and future plans to progress and develop the programs licensed to Loxo, including the timing of clinical trials. These statements involve significant risks and uncertainties, including those discussed in Array's most recent annual report filed on form 10-K, in Array's quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect Array's current expectations concerning future events, actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, the ability of Loxo and of Array to meet objectives tied to milestones and royalties; risks associated with Array's dependence on Loxo and other collaborators for the clinical development a
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
2. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
3. PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
4. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
5. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
6. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
7. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
8. Genomic Health Announces Results of Ten Studies in Breast, Prostate and Colon Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. ViewRays Chief Medical Officer Honored by American Society for Radiation Oncology (ASTRO)
10. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Tobramycin Market, 2010-2019" ... a traditional antibiotic whose eye drop and ointment are ... potential infection or inflammation caused by eye infection. Currently, ... are able to produce tobramycin, among which the Top ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... Seroquel) is an important drug for the treatment ... in 2000, quetiapine was listed in the Catalogue ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Ranibizumab ... Developed by Novartis, ranibizumab was approved by CFDA to ... Currently, only Lucentis, a product of Novartis, is available ... the first self- developed drug for the treatment of ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... 7, 2011 Akorn, Inc. (NASDAQ: AKRX ... 2011, to discuss third quarter 2011 results followed by a ... day before the market opens. Subject: , Akorn, Inc. ... 2011, at 10:00 a.m. Eastern TimeDomestic Callers: , (888) ...
... PARSIPPANY, N.J., Oct. 7, 2011 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated ... Drug Administration (FDA) seeking approval to market Morphine Sulfate ... mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, and ...
Cached Medicine Technology:Watson Confirms EMBEDA(R) Patent Challenge 2Watson Confirms EMBEDA(R) Patent Challenge 3
(Date:8/29/2015)... AZ (PRWEB) , ... August 30, 2015 , ... On ... College (EMCC), one of the 10 regionally accredited Maricopa Community Colleges , ... to network with college students pursuing employment information and opportunities. , The Expo has ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... AB (PRWEB) , ... August 29, 2015 , ... ... heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at ... such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
(Date:8/28/2015)... ... , ... With the goal of furthering music education programs in schools, the ... County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best ... the underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... How Eating Disorders Affect Loved Ones At ... The Remuda Cornerstone Bookstore on May 2, PHOENIX, ... the nation,s leading and largest inpatient,treatment center for women and ... with the authors of the new book "Distorted -,How a ...
... on human immune cell may be key to stopping infection ... at suppressing HIV target proteins lying on the virus itself, ... immune cells might work even better. , That,s because human ... the virus would have much less chance of mutating around ...
... More than 6,000 internists (doctors of internal medicine), ... meet in Washington, D.C., for Internal Medicine 2008, ... of Physicians (ACP), from May 15 - 17 ... Internal Medicine 2008 is the largest continuing medical ...
... 29 /PRNewswire-FirstCall/ - Traxxec,Ltd, the UK subsidiary of ... today announces that, in line with the licence ... at the Interpack conference,and trade show in Dusseldorf, ... will be present at this,meeting giving the Traxxec ...
... third of Downs syndrome children who wear bifocal lenses to ... for two years, according to new research from Cardiff University. ... Syndrome Research Unit has studied the reasons for poor focussing ... of the children in the study who adopted bifocals to ...
... April 29 Gunther von Hagens, BODY WORLDS, the,traveling ... this week. Though it will not be known if ... at BODY WORLDS in Los Angeles, or if,the honor ... in Milwaukee, or,Baltimore, or Manchester, England, the number is ...
Cached Medicine News:Health News:Authors Of New Critically Acclaimed Book 'Distorted' Share Their Journey From an Eating Disorder at a Book Signing Event in Wickenburg 2Health News:Researchers Tackle HIV From a New Angle 2Health News:Researchers Tackle HIV From a New Angle 3Health News:ACP hosts largest medical education meeting for general and subspecialty internists 2Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 2Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 3Health News:A life 'lens' ordinary 2Health News:Gunther Von Hagens' BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone 2Health News:Gunther Von Hagens' BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone 3
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
Uvex Patriot Frame...
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
Medicine Products: